Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F13640 for central neuropathic pain after spinal cord injury
NL-OMON31968Phase 2Withdrawn
- Sponsor
- Pierre Fabre Laboratories
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NLX-112 in central neuropathic pain (CNP), sponsored by Pierre Fabre Laboratories. Primary endpoint: Primary efficacy response. Planned start May 2008; status: withdrawn.
02
Drugs
NLX-112
03
Conditions
central neuropathic pain (CNP)
Beyond the preview
Go deeper on NL-OMON31968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31968.